Clinical prognostic factors in 1277 patients with neuroblastoma: Results of The European Neuroblastoma Study Group 'Survey' 1982-1992

European Journal of Cancer

Volumn 36, Issue 7, 2000, Pages 901-908

  Cotterill, S J ^a   Pearson, A D J ^a   Pritchard, J ^b   Foot, A B M ^c   Roald, B ^d   Kohler, J A ^e   Imeson, J ^f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^f UKCCSG Data Centre   (United Kingdom)

Author keywords

Ganglioneuroblastoma; Infant; Neuroblastoma; Prognosis

Indexed keywords

CATECHOLAMINE;

ARTICLE; BONE MARROW; CANCER STAGING; DEMOGRAPHY; FEMALE; FOLLOW UP; GENDER; HISTOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GANGLIONEUROBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; SEX DISTRIBUTION;

EID: 0034105523     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00058-7     Document Type: Article

References (35)

1. Stiller C.A., Allen M.B., Eatock E.M. Childhood cancer in Britain. The National Registry of childhood tumours and incidence rates 1978-1987 Eur. J. Cancer. 31A:1995;2028-2034.
2. Brodeur G.M., Azar C., Brother M.et al. Neuroblastoma: effect of genetic factors on prognosis and treatment. Cancer. 70:1992;1685-1694.
3. Look A.T., Hayes F.A., Shuster J.J.et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 9:1991;581-591.
4. Gilbert F., Balaban G., Moorhead P.et al. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet. Cytogenet. 7:1982;22-42.
5. Caron H., van Sluis P., van Hoeve M.et al. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nature Genet. 4:1993;187-190.
6. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med. Ped. Oncol. 24:1995;215-221.
7. Lastowska M., Cotterill S., Pearson A.D.J.et al. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. Eur. J. Cancer. 33:1997;1627-1633.
8. Kinnier Wilson L.M., Draper G.J. Neuroblastoma, its natural history and prognosis. a study of 487 cases Br. Med. J. 3:1974;301-307.
9. Evans A.E., Albo V., D'Angio G.J.et al. Factors influencing survival of children with non-metastatic neuroblastoma. Cancer. 38:1976;661-666.
10. Coldman A.J., Fryer C.J.H., Elwood J.M., Sonly M.J. Neuroblastoma. influences of age at diagnosis, stage, tumour site, and gender on prognosis Cancer. 46:1980;1896-1901.
11. Hayes F.A., Green A., Hustu H.O.et al. Surgicopathologic staging of neuroblastoma. prognostic significance of regional lymph node metastases J. Pediatr. 102:1983;59-62.
12. Shuster J.J., McWilliams N.B., Castleberry R.et al. Serum lactate dehydrogenase in childhood neuroblastoma. a Pediatric oncology group recursive partitioning study Am. J. Clin. Oncol. 15:1992;295-303.
13. Pinkerton CR, Pritchard J, de Kraker J, et al. ENSG 1: Randomised study of high dose melphalan in neuroblastoma. In Dickie K, Sptizer G, Jugannoth S, eds. Autologous Bone Marrow Transplantation. Texas, University of Texas Press, 1987.
14. de Kraker J., Pritchard J., Hartmann O., Ninane J. Single agent ifosfamide in patients with recurrent neuroblastoma (ENSG Study 2). Ped. Hematol. Oncol. 4:1987;101-104.
15. Kellie S.J., de Kraker J., Lilleyman J.S., Bowman A., Pritchard J. Ifosfamide in previously untreated disseminated neuroblastoma. results of study 3A of ENSG Euro. J. Cancer Clin. Oncol. 24:1988;903-908.
16. Hartmann O., Pinkerton C.R., Zucker J.M., Breatnach F., Philip T. Very high dose cisplatin and etoposide in children with untreated neuroblastoma. J. Clin. Oncol. 6:1988;44-50.
17. Pinkerton C.R., Zucker J.M., Hartmann O.et al. Short duration high dose alternating chemotherapy in metastatic neuroblastoma. (ENSG IIIC Induction Regime). Br. J. Cancer. 62:1990;319-323.
18. Pearson ADJ, Pinkerton CR, Lewis IJ. European Neuroblastoma Group Fifth Study (ENSG 5). A randomised study of dose intensity in stage 4 neuroblastoma over the age of one. Adv Neuroblastoma Res 1994, 354.
19. Shafford E.A., Rogers D.W., Pritchard J. Advanced neuroblastoma. improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26 J. Clin. Oncol. 2:1984;742-747.
20. Hayes F.A., Green A., Hustu H.O.et al. Surgicopathologic staging of neuroblastoma. prognostic significance of regional lymph node metastases. Journal of regional lymph node metastases J. Pediatr. 102:1983;59-62.
21. Evans A.E., D'Angio G.J., Sather H.N.et al. A comparison of four staging systems for localised and regional neuroblastoma. a report from the Children's Cancer Study Group J. Clin. Oncol. 8:1990;678-688.
22. Brodeur G.M., Seeger R.C., Barrett A. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J. Clin. Oncol. 6:1988;1874-1881.
23. Brodeur G.M., Pritchard J., Berthold F.et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment. J. Clin. Oncol. 11:1993;1466-1477.
24. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
25. Cox DR, Oakes D. Analysis of Survival Data. London, Chapman and Hall, 1984.
26. Cervera A., Kingston J.E., Malpas J.S. Late recurrence of neuroblastoma. a report of five cases and review of the literature Ped. Haematol. Oncol. 7:1990;311-322.
27. Cotterill SJ, Pearson ADJ, Pritchard J, et al. Prognosis for neuroblastoma patients surviving five years or more: a report from the European Neuroblastoma Study Group "Survey". Proc Adv Neuroblastoma, 1998.
28. De Bernardi B., Pianca C., Boni L.et al. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer. 70:1992;1625-1633.
29. Berthold F., Trechow R., Utsch S., Zieschang J. Prognostic factors in metastatic neuroblastoma. A mulivariate analysis of 182 cases. Am. J. Pediatr. Oncol. 14:1992;207-215.
30. Shuster J.J., McWilliams N.B., Castleberry R.et al. Serum lactate dehydrogenase in childhood neuroblastoma. a Paediatric Oncology Group recursive partitioning study Am. J. Clin. Oncol. 15:1992;295-303.
31. Reid M.M. Detection of bone marrow infiltration by neuroblastoma in clinical practice: how far have we come? Eur. J. Cancer. 30A:1994;134-135.
32. Pritchard J., Barnes J.M., Germond S.M., Wallendszus K.R. Gender and survival in neuroblastoma. Lancet. 8633:1989;328.
33. Pritchard J., Barnes J., Germond S.et al. Stage and urinary catecholamine metabolite excretion in neuroblastoma. European Neuroblastoma Study Group. Lancet. 8661:1989;514-515.
34. Matthay K.K., Villablanca J.G., Seeger R.C.et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplant, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341:1999;1165-1173.
35. Cheung N.K., Kushner B.H., Cheung I.Y.et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol. 16:1998;3053-3060.